CoChat

Progress in the Understanding of the Mechanism of Tamoxifen Resistance in Breast Cancer

Open access
Yao, Jingwei, Deng, Kun, Huang, Jialu, Zeng, Ruimin, Zuo, Jianhong · 2020 · Frontiers in Pharmacology
Cited by 167

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Tamoxifen is a drug commonly used in the treatment of breast cancer, especially for postmenopausal patients. However, its efficacy is limited by the development of drug resistance. Downregulation of estrogen receptor alpha (ERα) is an important mechanism of tamoxifen resistance. In recent years, with progress in research into the protective autophagy of drug-resistant cells and cell cycle regulators, major breakthroughs have been made in research on tamoxifen resistance. For a better understanding of the mechanism of tamoxifen resistance, protective autophagy, cell cycle regulators, and some transcription factors and enzymes regulating the expression of the estrogen receptor are summarized in this review. In addition, recent progress in reducing resistance to tamoxifen is reviewed. Finally, we discuss the possible research directions into tamoxifen resistance in the future to provide assistance for the clinical treatment of breast cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fphar.2020.592912

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 88

  1. Ali, 2016, Current management strategies in breast cancer by targeting key altered molecular players, Front. Oncol., 6, 45, 10.3389/fonc.2016.00045 · DOI
  2. Antonioli, 2017, Emerging mechanisms in initiating and terminating autophagy, Trends Biochem. Sci., 42, 28, 10.1016/j.tibs.2016.09.008 · DOI · Paper page
  3. Binkhorst, 2012, Individualization of tamoxifen treatment for breast carcinoma, Clin. Pharmacol. Ther., 92, 431, 10.1038/clpt.2012.94 · DOI
  4. Block, 2012, Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells, Int. J. Oncol., 41, 1845, 10.3892/ijo.2012.1591 · doi:10.3892/ijo.2012.1591
  5. Bray, 2018, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA A Cancer J. Clin., 68, 394, 10.3322/caac.21492 · DOI · Paper page
  6. Cheng, 2017, Aspirin regulation of c-myc and cyclinD1 proteins to overcome tamoxifen resistance in estrogen receptor-positive breast cancer cells, Oncotarget, 8, 30252, 10.18632/oncotarget.16325 · DOI
  7. Cheng, 2019, Icariin induces apoptosis by suppressing autophagy in tamoxifen-resistant breast cancer cell line MCF-7/TAM, Breast Cancer, 26, 766, 10.1007/s12282-019-00980-5 · DOI
  8. Choi, 2016, Co-treatment of LY294002 or MK-2206 with AZD5363 attenuates AZD5363-induced increase in the level of phosphorylated AKT, Ar, 36, 5849, 10.21873/anticanres.11170 · doi:10.21873/anticanres.11170
  9. Choi, 2018, Role of RBP2-induced ER and IGF1R-ErbB signaling in tamoxifen resistance in breast cancer, J. Natl. Cancer Inst., 110, 400, 10.1093/jnci/djx207 · DOI
  10. Cook, 2011, Autophagy and endocrine resistance in breast cancer, Expet Rev. Anticancer Ther., 11, 1283, 10.1586/era.11.111 · DOI · Paper page
  11. Cristofanilli, 2016, Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial, Lancet Oncol., 17, 425, 10.1016/S1470-2045(15)00613-0 · DOI · Paper page
  12. Das, 2019, Lactate dehydrogenase A regulates autophagy and tamoxifen resistance in breast cancer, Biochim. Biophys. Acta Mol. Cell Res., 1866, 1004, 10.1016/j.bbamcr.2019.03.004 · DOI
  13. Elias, 2015, Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy, Oncogene, 34, 1919, 10.1038/onc.2014.138 · DOI
  14. Ferraiuolo, 2017, The cyclin-like protein, SPY1, regulates the ERα and ERK1/2 pathways promoting tamoxifen resistance, Oncotarget, 8, 23337, 10.18632/oncotarget.15578 · DOI
  15. Gao, 2018, LEM4 confers tamoxifen resistance to breast cancer cells by activating cyclin D-CDK4/6-Rb and ERα pathway, Nat. Commun., 9, 4180, 10.1038/s41467-018-06309-8 · DOI
  16. Giordano, 2011, Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression, Oncogene, 30, 4129, 10.1038/onc.2011.124 · DOI
  17. Gong, 2018, BQ323636.1, a novel splice variant to NCOR2, as a predictor for tamoxifen-resistant breast cancer, Clin. Canc. Res., 24, 3681, 10.1158/1078-0432.CCR-17-2259 · DOI
  18. Gonzalez-Malerva, 2011, High-throughput ectopic expression screen for tamoxifen resistance identifies an atypical kinase that blocks autophagy, Proc. Natl. Acad. Sci. USA, 108, 2058, 10.1073/pnas.1018157108 · DOI
  19. Guney Eskiler, 2018, Solid lipid nanoparticles: reversal of tamoxifen resistance in breast cancer, Eur. J. Pharmaceut. Sci., 120, 73, 10.1016/j.ejps.2018.04.040 · DOI
  20. Gwak, 2017, Expression of embryonal stem cell transcription factors in breast cancer: oct4 as an indicator for poor clinical outcome and tamoxifen resistance, Oncotarget, 8, 36305, 10.18632/oncotarget.16750 · DOI
  21. He, 2019, The miR-186-3p/EREG axis orchestrates tamoxifen resistance and aerobic glycolysis in breast cancer cells, Oncogene, 38, 5551, 10.1038/s41388-019-0817-3 · DOI
  22. Heckler, 2014, ERK/MAPK regulates ERRγ expression, transcriptional activity and receptor-mediated tamoxifen resistance in ER+ breast cancer, FEBS J., 281, 2431, 10.1111/febs.12797 · DOI
  23. Hosford, 2014, Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways, Pharmgenomics Pers Med, 7, 203, 10.2147/PGPM.S52762 · DOI · Paper page
  24. Huang, 2019, Targeting Pin1 by all-trans retinoic acid (ATRA) overcomes tamoxifen resistance in breast cancer via multifactorial mechanisms, Front. Cell Dev. Biol., 7, 322, 10.3389/fcell.2019.00322 · DOI
  25. Ito, 2012, Alteration of Y-box binding protein-1 expression modifies the response to endocrine therapy in estrogen receptor-positive breast cancer, Breast Canc. Res. Treat., 133, 145, 10.1007/s10549-011-1731-8 · doi:10.1007/s10549-011-1731-8
  26. Jeong, 2019, EGFR is a therapeutic target in hormone receptor-positive breast cancer, Cell. Physiol. Biochem., 53, 805, 10.33594/000000174 · doi:10.33594/000000174
  27. Jeselsohn, 2017, Embryonic transcription factor SOX9 drives breast cancer endocrine resistance, Proc. Natl. Acad. Sci. USA, 114, E4482, 10.1073/pnas.1620993114 · DOI
  28. Jia, 2018, KLF4 overcomes tamoxifen resistance by suppressing MAPK signaling pathway and predicts good prognosis in breast cancer, Cell. Signal., 42, 165, 10.1016/j.cellsig.2017.09.025 · DOI
  29. Jiang, 2020, Dying tumor cell-derived exosomal miR-194-5p potentiates survival and repopulation of tumor repopulating cells upon radiotherapy in pancreatic cancer, Mol. Canc., 19, 68, 10.1186/s12943-020-01178-6 · DOI
  30. Jögi, 2019, Expression of HIF-1α is related to a poor prognosis and tamoxifen resistance in contralateral breast cancer, PLoS One, 14, e0226150, 10.1371/journal.pone.0226150 · DOI · Paper page
  31. John, 2008, Regulation of estrogenic effects by beclin 1 in breast cancer cells, Canc. Res., 68, 7855, 10.1158/0008-5472.CAN-07-5875 · DOI
  32. Karlsson, 2019, PTPN2 deficiency along with activation of nuclear Akt predict endocrine resistance in breast cancer, J. Canc. Res. Clin. Oncol., 145, 599, 10.1007/s00432-018-2810-6 · doi:10.1007/s00432-018-2810-6
  33. Kim, 2006, Cancer's molecular sweet tooth and the warburg effect: figure 1, Canc. Res., 66, 8927, 10.1158/0008-5472.CAN-06-1501 · DOI · Paper page
  34. Kim, 2015, Differential effect of EGFR inhibitors on tamoxifen-resistant breast cancer cells, Oncol. Rep., 34, 1613, 10.3892/or.2015.4116 · DOI
  35. Kulkoyluoglu-Cotul, 2019, Combined targeting of estrogen receptor alpha and XPO1 prevent akt activation, remodel metabolic pathways and induce autophagy to overcome tamoxifen resistance, Cancers, 11, 479, 10.3390/cancers11040479 · DOI
  36. Kumar, 2018, N-desmethyl tamoxifen and quercetin-loaded multiwalled CNTs: a synergistic approach to overcome MDR in cancer cells, Mater. Sci. Eng. C, 89, 274, 10.1016/j.msec.2018.03.033 · DOI
  37. Kuo, 2013, SIRT1 suppresses breast cancer growth through downregulation of the Bcl-2 protein, Oncol. Rep., 30, 125, 10.3892/or.2013.2470 · DOI
  38. Lee, 2018, MTA1 is a novel regulator of autophagy that induces tamoxifen resistance in breast cancer cells, Autophagy, 14, 812, 10.1080/15548627.2017.1388476 · DOI
  39. Lee, 2017, Cold atmospheric plasma restores tamoxifen sensitivity in resistant MCF-7 breast cancer cell, Free Radic. Biol. Med., 110, 280, 10.1016/j.freeradbiomed.2017.06.017 · DOI
  40. Li, Tumor‐associated macrophages secrete CC‐chemokine ligand 2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer, Canc. Sci., 111, 47, 10.1111/cas.14230 · DOI · Paper page
  41. Li, ERalpha36 as a potential therapeutic target for tamoxifen-resistant breast cancer cell line through EGFR/ERK signaling pathway, Canc. Manag. Res., 12, 265, 10.2147/CMAR.S226410 · DOI
  42. Li, 2016, Brachyury promotes tamoxifen resistance in breast cancer by targeting SIRT1, Biomed. Pharmacother., 84, 28, 10.1016/j.biopha.2016.09.011 · doi:10.1016/j.biopha.2016.09.011
  43. Li, 2019, Repositioning aspirin to treat lung and breast cancers and overcome acquired resistance to targeted therapy, Front Oncol, 9, 1503, 10.3389/fonc.2019.01503 · DOI
  44. Li, 2018, C-Cbl reverses HER2-mediated tamoxifen resistance in human breast cancer cells, BMC Canc., 18, 507, 10.1186/s12885-018-4387-5 · DOI
  45. Lin, 2018, Oestrogen receptor-regulated glutathione S-transferase mu 3 expression attenuates hydrogen peroxide-induced cytotoxicity, which confers tamoxifen resistance on breast cancer cells, Breast Canc. Res. Treat., 172, 45, 10.1007/s10549-018-4897-5 · doi:10.1007/s10549-018-4897-5
  46. Liu, 2019, The correlation between autophagy and tamoxifen resistance in breast cancer, Int. J. Clin. Exp. Pathol., 12, 2066
  47. Liu, 2009, The critical role of the class III histone deacetylase SIRT1 in cancer, Canc. Res., 69, 1702, 10.1158/0008-5472.CAN-08-3365 · DOI · Paper page
  48. Lopez-Tarruella, 2007, The dynamics of estrogen receptor status in breast cancer: re-shaping the paradigm, Clin. Canc. Res., 13, 6921, 10.1158/1078-0432.CCR-07-1399 · DOI
  49. Lui, 2016, Everolimus downregulates estrogen receptor and induces autophagy in aromatase inhibitor-resistant breast cancer cells, BMC Canc., 16, 487, 10.1186/s12885-016-2490-z · DOI
  50. Lv, 2015, Expression and localization of estrogen receptor in human breast cancer and its clinical significance, Cell Biochem. Biophys, 71, 63, 10.1007/s12013-014-0163-6 · doi:10.1007/s12013-014-0163-6
  51. Maczis, 2018, Sphingosine kinase 1 activation by estrogen receptor alpha36 contributes to tamoxifen resistance in breast cancer, J. Lipid Res., 59, 2297, 10.1194/jlr.M085191 · DOI
  52. Mansouri, Clinical evidence on the magnitude of change in growth pathway activity in relation to tamoxifen resistance is required, Curr. Cancer Drug Targets, 18, 668, 10.2174/1568009617666170808110820 · DOI
  53. Mansouri, A review on the role of VEGF in tamoxifen resistance, Anticancer Agents Med. Chem., 18, 2006, 10.2174/1871520618666180911142259 · doi:10.2174/1871520618666180911142259
  54. Maqbool, 2020, Overcoming tamoxifen resistance in oestrogen receptor-positive breast cancer using the novel thiosemicarbazone anti-cancer agent, DpC, Br. J. Pharmacol., 177, 2365, 10.1111/bph.14985 · DOI
  55. Maynadier, 2016, Combination treatment with proteasome inhibitors and antiestrogens has a synergistic effect mediated by p21WAF1 in estrogen receptor-positive breast cancer, Oncol. Rep., 36, 1127, 10.3892/or.2016.4873 · DOI
  56. Mishra, 2018, Reactivation of cAMP pathway by PDE4D inhibition represents a novel druggable Axis for overcoming tamoxifen resistance in ER-positive breast cancer, Clin. Canc. Res., 24, 1987, 10.1158/1078-0432.CCR-17-2776 · DOI
  57. Nagelkerke, 2014, LAMP3 is involved in tamoxifen resistance in breast cancer cells through the modulation of autophagy, Endocr. Relat. Canc., 21, 101, 10.1530/ERC-13-0183 · DOI
  58. Oh, 2010, Inhibition of angiogenesis by quercetin in tamoxifen-resistant breast cancer cells, Food Chem. Toxicol., 48, 3227, 10.1016/j.fct.2010.08.028 · DOI
  59. Omarjee, 2017, The molecular mechanisms underlying the ERalpha-36-mediated signaling in breast cancer, Oncogene, 36, 2503, 10.1038/onc.2016.415 · DOI
  60. Peng, 2017, Linc-RoR promotes MAPK/ERK signaling and confers estrogen-independent growth of breast cancer, Mol. Canc., 16, 161, 10.1186/s12943-017-0727-3 · DOI · Paper page
  61. Putluri, 2014, Pathway-centric integrative analysis identifies RRM2 as a prognostic marker in breast cancer associated with poor survival and tamoxifen resistance, Neoplasia, 16, 390, 10.1016/j.neo.2014.05.007 · DOI
  62. Qi, 2017, Sensitization of tamoxifen-resistant breast cancer cells by Z-ligustilide through inhibiting autophagy and accumulating DNA damages, Oncotarget, 8, 29300, 10.18632/oncotarget.16832 · DOI
  63. Rugo, 2016, Endocrine therapy for hormone receptor-positive metastatic breast cancer: American society of clinical oncology guideline, J. Clin. Oncol., 34, 3069, 10.1200/JCO.2016.67.1487 · DOI · Paper page
  64. Scott, 1998, Identification and characterization of two putative human arginine methyltransferases (HRMT1L1 and HRMT1L2), Genomics, 48, 330, 10.1006/geno.1997.5190 · DOI · Paper page
  65. Shen, 2018, Protein arginine N-methyltransferase 2 reverses tamoxifen resistance in breast cancer cells through suppression of ER-alpha36, Oncol. Rep., 39, 2604, 10.3892/or.2018.6350 · doi:10.3892/or.2018.6350
  66. Shi, 2013, Resveratrol sensitizes tamoxifen in antiestrogen-resistant breast cancer cells with epithelial-mesenchymal transition features, Int. J. Mol. Sci., 14, 15655, 10.3390/ijms140815655 · DOI
  67. Shimoda, 2017, Endocrine sensitivity of estrogen receptor-positive breast cancer is negatively correlated with aspartate-beta-hydroxylase expression, Canc. Sci., 108, 2454, 10.1111/cas.13416 · doi:10.1111/cas.13416
  68. Sun, 2015, Autophagy facilitates multidrug resistance development through inhibition of apoptosis in breast cancer cells, Neoplasma, 62, 199, 10.4149/neo_2015_025 · DOI
  69. Thomas, 2013, Efficacy of histone deacetylase and estrogen receptor inhibition in breast cancer cells due to concerted down regulation of Akt, PLoS One, 8, e68973, 10.1371/journal.pone.0068973 · DOI
  70. Tong, 2010, ER-alpha36, a novel variant of ER-alpha, mediates estrogen-stimulated proliferation of endometrial carcinoma cells via the PKCdelta/ERK pathway, PLoS One, 5, e15408, 10.1371/journal.pone.0015408 · DOI
  71. Vargo-Gogola, 2007, Modelling breast cancer: one size does not fit all, Nat. Rev. Canc., 7, 10.1038/nrc2193 · DOI · Paper page
  72. Vaziri-Gohar, 2017, IGF-1 receptor modulates FoxO1-mediated tamoxifen response in breast cancer cells, Mol. Canc. Res., 15, 489, 10.1158/1541-7786.MCR-16-0176 · DOI
  73. Viedma-Rodriguez, 2014, Mechanisms associated with resistance to tamoxifen in estrogen receptor-positive breast cancer (review), Oncol. Rep., 32, 3, 10.3892/or.2014.3190 · DOI · Paper page
  74. Wang, 2020, Effect of aspirin use on neoadjuvant chemoradiotherapy for rectal cancer: a meta-analysis with trial sequential analysis, J. Canc. Res. Clin. Oncol., 146, 2161, 10.1007/s00432-020-03222-w · DOI
  75. Wang, 2015, Quercetin reverses tamoxifen resistance in breast cancer cells, J BUON, 20, 707
  76. Wang, 2019, The long noncoding RNA H19 promotes tamoxifen resistance in breast cancer via autophagy, J. Hematol. Oncol., 12, 81, 10.1186/s13045-019-0747-0 · DOI · Paper page
  77. Woo, 2016, Dichloroacetate potentiates tamoxifen-induced cell death in breast cancer cells via downregulation of the epidermal growth factor receptor, Oncotarget, 7, 59809, 10.18632/oncotarget.10999 · DOI
  78. Wu, 2020, Compound C enhances the anticancer effect of aspirin in HER-2-positive breast cancer by regulating lipid metabolism in an AMPK-independent pathway, Int. J. Biol. Sci., 16, 583, 10.7150/ijbs.39936 · DOI
  79. Xue, 2019, HDAC5-mediated deacetylation and nuclear localisation of SOX9 is critical for tamoxifen resistance in breast cancer, Br. J. Canc., 121, 1039, 10.1038/s41416-019-0625-0 · DOI
  80. Ye, 2019, Epigenetic silencing of SALL2 confers tamoxifen resistance in breast cancer, EMBO Mol. Med., 11, e10638, 10.15252/emmm.201910638 · DOI
  81. Yin, 2017, GPER promotes tamoxifen-resistance in ER+ breast cancer cells by reduced Bim proteins through MAPK/Erk-TRIM2 signaling axis, Int. J. Oncol., 51, 1191, 10.3892/ijo.2017.4117 · doi:10.3892/ijo.2017.4117
  82. Yin, 2014, Disruption of the ER-alpha36-EGFR/HER2 positive regulatory loops restores tamoxifen sensitivity in tamoxifen resistance breast cancer cells, PLoS One, 9, e107369, 10.1371/journal.pone.0107369 · DOI
  83. Yu, 2019, Cell division cycle associated 8 is a key regulator of tamoxifen resistance in breast cancer, J Breast Cancer, 22, 237, 10.4048/jbc.2019.22.e29 · doi:10.4048/jbc.2019.22.e29
  84. Zhang, 2013, Estrogen receptor-alpha variant, ER-alpha36, is involved in tamoxifen resistance and estrogen hypersensitivity, Endocrinology, 154, 1990, 10.1210/en.2013-1116 · DOI
  85. Zhang, 2020, Aspirin-targeted PD-L1 in lung cancer growth inhibition, Thorac Cancer, 11, 1587, 10.1111/1759-7714.13433 · DOI
  86. Zhang, 2018, IGF1R signaling drives antiestrogen resistance through PAK2/PIX activation in luminal breast cancer, Oncogene, 37, 1869, 10.1038/s41388-017-0027-9 · DOI
  87. Zhu, 2018, Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1, Nat. Commun., 9, 1595, 10.1038/s41467-018-03951-0 · DOI · Paper page
  88. Zuo, 2011, Activation of EGFR promotes squamous carcinoma SCC10A cell migration and invasion via inducing EMT-like phenotype change and MMP-9-mediated degradation of E-cadherin, J. Cell. Biochem., 112, 2508, 10.1002/jcb.23175 · DOI · Paper page

Cited by

See all 167

Metadata

Authors
Yao, J., Deng, K., Huang, J., Zeng, R., & Zuo, J.
Venue
Frontiers in Pharmacology
Published
2020-12-09
Volume
11
Pages
592912-592912
ISSN
1663-9812 (ISSN-L)
OpenAlex
W3113117605
Cited by
167
References
2
FWCI
9.03
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Progress in the Understanding of the Mechanism of Tamoxifen Resistance in Breast Cancer. https://app.cochat.ai/papers/10.3389/fphar.2020.592912
The paper
Yao, J., Deng, K., Huang, J., Zeng, R., & Zuo, J. (2020). Progress in the Understanding of the Mechanism of Tamoxifen Resistance in Breast Cancer. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2020.592912

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.